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CONTEMPORARY REVIEW
Exploring Refractoriness as an Adjunctive 
Electrical Biomarker for Staging of Atrial 
Fibrillation
Lianne N. van Staveren, MD; Natasja M. S. de Groot , MD, PhD
ABSTRACT: Patients diagnosed with the same subtype of atrial fibrillation according to our current classification system may 
differ in symptom severity, severity of the arrhythmogenic substrate, and response to antiarrhythmic therapy. Hence, there 
is a need for an electrical biomarker as an indicator of the arrhythmogenic substrate underlying atrial fibrillation enabling 
patient-tailored therapy. The aim of this review is to investigate whether atrial refractoriness, a well-known electrophysiological 
parameter that is affected by electrical remodeling, can be used as an electrical biomarker of the arrhythmogenic substrate 
underlying atrial fibrillation. We discuss methodologies of atrial effective refractory period assessment, identify which changes 
in refractoriness-related parameters reflect different degrees of electrical remodeling, and explore whether these parameters 
can be used to predict clinical outcomes.
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Patients diagnosed with the same subtype of atrial fibrillation (AF) according to our current classifica-tion system may differ in symptom severity, se-
verity of the arrhythmogenic substrate, and response 
to antiarrhythmic therapy.1 Paradoxally, patients with 
different AF subtypes may have similar severities of 
the arrhythmogenic substrates. Hence, there is a need 
for an electrical biomarker as an indicator of the ar-
rhythmogenic substrate underlying AF. The availability 
of such an electrical biomarker enables staging of AF 
and will improve patient-tailored therapy.
A well-known electrophysiological parameter that 
is affected by AF-induced electrical remodeling is 
the atrial effective refractory period (AERP). AERP 
shortens in response to accelerated activation fre-
quencies, so-called rate adaptation of refractoriness. 
After deceleration, AERP prolongs again but even 
after sufficient time for recovery, AERP in patients 
with a history of AF remains relatively shorter. This 
indicates that AF inflicts permanent damage on car-
diomyocytes’ rate adaptation capacities. In addition, 
electrical remodeling can manifest heterogeneously 
throughout the atria, and subsequent dispersion 
of refractoriness is widely acknowledged as a key 
player in the pathophysiology of both onset and 
maintenance of AF.
If refractoriness is affected gradually as the arrhyth-
mogenic substrate progresses, it could potentially be 
used as a biomarker for AF.
The aim of this review is to investigate whether atrial 
refractoriness can be used as an electrical biomarker 
of the arrhythmogenic substrate underlying AF. We 
discuss methodologies of AERP assessment, identify 
which changes in refractoriness-related parameters 
reflect different degrees of electrical remodeling, and 
explore whether these parameters can be used to pre-
dict clinical outcomes.
RATE DEPENDENCY OF AERP
As mentioned above, AERP is rate dependent and 
adapts to the preceding cycle length. Duration of AERP 
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is directly related to the action potential duration (APD).2 
Acute increase in activation rate during rapid stimulation 
or tachyarrhythmia causes intracellular Ca2+ overload in 
the cardiomyocytes.3 This triggers downregulation of 
L-type Ca2+ channels and upregulation of slow rectifier K+ 
currents, resulting in faster repolarization and thus AERP 
and APD shortening, so-called rate adaptation.4,5
Rate adaptation was first demonstrated in 20 
patients without structural heart disease in whom 
episodes of pacing-induced AF shortened AERP at 
basic cycle lengths (BCLs) of 500 and 300 ms from 
216±17 to 191±30  ms (P<0.0001) and 206±23 to 
175±30  ms (P<0.0001), respectively.6 After a mean 
period of 8.4±0.3 minutes, AERPs were restored to 
pre-AF values. Rate adaptation occurs immediately 
after cycle length shortening2 and is progressive 
when the tachycardia persists. In the goat model of 
AF, the AERP shortened from 131±11 to 106±17 ms 
after 24 hours of induced AF but shortened even fur-
ther to 70±12 ms after 43±34 days of pacing.7 The 
shortest possible AERP is unknown, yet in both ex-
perimental and clinical studies, a minimal AERP of 50 
to 60 ms is commonly applied.8,9 However, the ratio-
nale for this cutoff value remains unclear, as there are 
no reports on assessment of the minimum duration 
of refractoriness.
Beat-to-beat changes in APD during steady-state 
pacing (APD alternans), related to cyclic fluctuations 
in intracellular Ca2+ concentrations, were related to 
onset of AF in humans.10–12 Varying APD morphology 
was most prominent in the early repolarization phase, 
and recently involvement of changes in total outward 
K+ currents was demonstrated as well in human left 
atria (LA). During simulation of an action potential, 
using a mathematical model of human atrial cardio-
myocytes, replacement of K+ channels type Kv4.3 by 
slower recovering type Kv1.4 (more fetal or undiffer-
entiated variant), as occurs because of mechanical 
or endocrinological stress, increased occurrence of 
APD alternans.13 APD alternans occurs only at rapid 
pacing frequencies; in 12 patients with persistent atrial 
fibrillation (peAF), 13 patients with paroxysmal atrial 
fibrillation (PAF), and 8 controls, APD alternans started 




In general, refractoriness is determined by extrastim-
uli (S2) pacing during electrophysiological studies 
and defined as the longest S1–S2 interval that fails 
to propagate a response. Pacing stimuli open volt-
age-gated Na+ channels, enabling Na+ influx, result-
ing in depolarization.14 The relation between stimulus 
strength and AERP was examined in 25 patients with 
a history of syncope and atrial or ventricular tach-
yarrhythmias; shortening of AERP attributable to in-
creasing stimulus strength occurred progressively up 
to stimuli of relatively 5.3±1.7 mA at a BCL of 600 ms 
and 5.9±1.5 mA at a BCL of 300 ms (P=NS). At this 
point, refractoriness had been reached and AERP 
did not shorten further as stimulus strength was 
increased up to 10  mA.15 Thus, there is an inverse 
relationship between AERP and stimulation current. 
Therefore, AERP can be reliably compared between 
patients only when similar stimulus strengths are ap-
plied during pacing.
Reliability of the premature stimulus methodology 
for AERP determination in nonuniform anisotropic car-
diac tissue is questionable, as previously discussed by 
Spach et al.16 The AERP is commonly defined as the 
interval between pacing stimuli rather than the interval 
between atrial activations measured at the recording 
site. Therefore, frequency-dependent conduction de-
lays during premature stimulation arising between the 
pacing and recording site result in apparently shorter 
AERPs. Distance between the pacing and recording 
electrode should therefore also be taken into account 
when comparing AERP between different atrial sites, 
but this is rarely reported.
Another parameter that has been used to esti-
mate AERP is time to reach 90% of the action poten-
tial repolarization (APD90). The reliability of APD90 
measurements remains debatable, as when both 
AERP and ADP90 are determined in the same in-
dividual, substantial differences were observed.10 
Comparing APD90 to AERP at a BCL of 600  ms, 
for example, 226±16  ms versus 211±24  ms in pa-
tients with persistent AF (peAF, N=18), 250±35  ms 
versus 233±29 ms in patients with PAF (N=14), and 
258±25  ms versus 229±19  ms in control subjects 
(N=9), respectively, were measured. Hence, these 
observations indicate that the APD90 is not a suit-
able substitute for AERP. Validity of monophasic ac-
tion potential catheters are debated as well, as they 
are prone to movement artefacts.17
Nonstandard Abbreviations and Acronyms
AERP atrial effective refractory period
APD action potential duration
APD90  action potential duration at 90% of 
repolarization
BCL basic cycle length
PAF paroxysmal atrial fibrillation
peAF persistent atrial fibrillation
PV pulmonary veins
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For both methodologies of measuring refractori-
ness, using progressively faster steady-state pacing 
may result in different AERPs or APDs than the extra-
stimulus methodology,18 as refractoriness has more 
time to adjust. Moreover, reports on the occurrence 
of APD alternans indicate that in some patients, repo-
larization may be temporally irregular even during con-
stant stimulation rate.19
INDIRECT DETERMINATION OF AERP
As prior experimental and clinical studies demon-
strated that the minimum or fifth percentile of the inter-
val histogram corresponded to the AERP determined 
during extrastimuli protocols, these values have been 
widely accepted as a surrogate measure for AERP. In 
an isolated perfused canine model (N=8), high-den-
sity (256 sites) epicardial AF recordings with a dura-
tion of 10 seconds proved sufficient to estimate AERP 
by using the minimum AF cycle length.20 Likewise, in 
patients with PAF (N=25), the fifth percentile approxi-
mated AERP when calculated from at least 100 con-
secutive fibrillation intervals measured endovascular at 
the high right atrium (RA), low RA, coronary sinus, or 
oval fossa.21
Excitation of cardiomyocytes directly after the AERP 
is mandatory to derive the AERP from an interval his-
togram. However, as reflected by the large variation in 
fibrillation intervals, cardiomyocytes are probably rarely 
excited at the exact moment that refractoriness ends, 
and as a consequence, an excitable gap is often pres-
ent.22 Also, when the fibrillation rate is low or regular, lon-
ger recordings may be required to estimate the AERP.
Other ways to determine AERP during AF include 
slow fixed-rate pacing and entrainment. Duytschaever 
et al8 used an experimental goat model to compare 
various methodologies including an extrastimuli pro-
tocol (AERP, 70±12  ms); entrainment (77±17  ms; R2 
correlation coefficient=0.88; P<0.01), fixed-rate pacing 
(71±17  ms; R2=0.84; P<0.01) and the fifth percentile 
AF cycle length (77±12 ms, R2=90, P<0.01) and found 
that all approaches correlated well with the extrastimuli 
“gold standard.”
Even though these results look promising, it is im-
portant to realize that the shortest interval measured 
probably represents the shortest possible AERP of 
local cardiomyocytes. The refractory period changes 




Table 1 provides an overview of experimental and clini-
cal studies assessing refractoriness in nonremodeled 
hearts.2,6,7,10,21,23–28 In clinical studies, at BCLs of 
400, 500, and 600 ms, AERP ranges from 213±35 to 
266±37 ms, 215±29 to 277±42 ms, and from 227±20 
to 291±53 ms, respectively. This table also shows that 
despite the fact that humans and animals share com-
parable cardiac dimensions, absolute AERPs may still 
differ.
For example, at a BCL of 400  ms, AERP was 
150±8 ms in canine RA and 146±19 ms in the LA and 
RA of goats,7 compared with AERPs ranging from 
213±35 to 266±37 ms (BCL, 400 ms) in human non-
remodeled atria. Extrapolation of refractoriness mea-
sures in animal models to humans should thus be 
done with caution.
Official reference values for “normal” refractoriness 
are scarce. As previously discussed, only Daoud et al6 
assessed refractoriness in nonremodeled human atria. 
AERP was determined in the RA of 20 patients without 
a history of AF (stimulus: 3× diastolic threshold; mean 
threshold, 0.7±0.2 mA). At BCLs of 500 and 350 ms, 
AERPs were 216±17 and 206±23 ms, respectively.
Various factors may influence AERP assessed 
during electrophysiology studies such as magnitude of 
decrements in extrastimuli and cardio-active medication 
like antiarrhythmic drugs or anesthetics.23 In addition, 
refractoriness is dependent on the measuring site, and 
AERPs may vary from region to region.29,30 Finally, hys-
teresis of refractoriness measurements may also cause 
discrepancy in study results, as it has been reported that 
incremental extrastimuli lead to longer AERPs or APDs 
than decremental extrastimuli in a canine model.31,32 
However, as studies using both approaches to deter-
mine AERP in human atria are not available from the 
literature, head-to-head comparison of incremental and 
decremental extrastimuli protocols is not possible.
SPATIAL DISTRIBUTION OF AERP IN 
NONREMODELED ATRIA
In adult canines, APD in the RA shortened as dis-
tance to the sinus node increased.33 In another study, 
AERPs measured using basket catheters in the lower 
part of the canine RA were indeed longer compared 
with the high part of the RA (BCL 400 ms, 111±23 ms 
versus 94±24 ms; P<0.01; BCL 300 ms, 104±20 ms 
versus 96±23 ms; P<0.01). AERP was also longer at 
the smooth posteroseptal RA than at the trabeculated 
RA free wall (102±25 ms versus 97±17 ms; P<0.05) at 
a BCL of 300 ms, suggesting that AERP may be de-
pendent of atrial wall morphology as well.34 However, 
at a BCL of 400 ms AERP did not differ between the 
smooth and trabeculated wall.
Satoh and Zipes35 found longer AERPs in the thin-
ner medial RA free wall compared with the thicker lateral 
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versus 133±8 ms; P<0.01) in 9 anesthetized open-chest 
dogs, suggesting that atrial refractoriness is related to 
wall thickness. Local variation in refractoriness were, 
however, not found in the RA of newborn dogs, indicating 
that regional AERP differences develop during aging.16
AERP distribution was described in more detailed by 
Vollmann et al.36 In 6 goats, AERPs were assessed at 
11 epicardial regions, including the RA and LA free wall 
(array, 1×1.5 cm, 12 electrodes) and Bachmann’s bun-
dle area (array, 10×1.3 cm, 56 electrodes). AERP was 
longest at mid-Bachmann’s bundle (AERP, 185±6 ms) 
and shortest at the LA free wall (AERP, 141±5  ms; 
P<0.001). Other experimental studies also found that 
AERPs in the LA are shorter.8,29,37–39





Decremental Stimulus Strength Location BCL (ms) AERP (ms) Comment
Experimental studies




1995, Morillo24 Dogs, 10 Decremental, 10-ms steps 2×DT RA 300 147±11 Small study 
population
400 150±8
1995, Wijffels7 Goats, 12 Incremental, 2-ms steps 4× threshold RA, LA 400 146±19 Small study 
population
Clinical studies









1995, Capucci21 10 Decremental, 1-ms steps 2.5×DT RA, CS, 
or LA
400 266±37 Small study 
population
2001, Brundel23 13 … … LAA, RAA 400 252±34 Anesthesia
1987, Soni2 11 Decremental, steps: - 3 mA RA 436±81 225±29 BCL not 
standardized
1995, Capucci21 10 Decremental, 1-ms steps 2.5×DT RA, CS, 
or LA
500 267±42 Small study 
population









62 Decremental, 10-ms steps 2×DT RA, CS 500 215±29
1995, Capucci21 10 Decremental, 1-ms steps 2.5×DT RA, CS or 
LA
600 281±35 Small study 
population
1998, Chen27 20 Incremental, 10-ms steps 2×DT RA 600 211±26
2001, Brundel23 13 … … LAA, RAA 600 291±53 Anesthetics
2002, Kim10 9 … … RA (6 
sites)
600 227±20 Small study 
population
2016, Lee28 1308 Decremental, 10-ms steps 2× threshold RA 600 (in 
93%)
233±31 BCL not 
standardized
1985, Alboni26 20 Decremental, 10-ms steps 2×DT RA 680±68 211±27 BCL not 
standardized
1987, Soni2 11 Decremental, steps: - 3 mA RA 709±80 250±38 BCL not 
standardized
“-” indicates no details provided; AERP, atrial effective refractory period; BCL, basic drive cycle length; CS, coronary sinus; DT, diastolic threshold; LA, left 
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Measurements of AERP at a BCL of 120 ms com-
bined with tissue analysis in 9 mice atria demon-
strated that LA AERP was shorter than the RA AERP 
(16.9±0.9 ms versus 19.8±1 ms; P<0.05) and that both 
total outward and inward rectifier K current density 
were increased in the LA suggestive of enhanced ca-
pacity for rate adaptation.39
Clinical studies have reported regional differences 
in AERP, but it is usually not measured at a high-reso-
lution scale, or sites at which AERP is the shortest or 
longest are not described.
Remarkably, in few clinical studies, regional differ-
ences in AERPs were compared between the nonre-
modeled LA and RA. In 22 patients without AF, AERP 
was longer in the distal coronary sinus (BCL, 500 ms; 
AERP, 244±30 ms) than in the RA (219±20 ms; P<0.01).40 
This difference in AERP between the RA and coronary 
sinus was also confirmed by other clinical studies.30,37
These observations contrast with many experimen-
tal studies assessing regional differences in AERP, as 
mentioned above. However, patients in whom AF was 
repetitively induced were excluded, which may have 
caused a selection bias. There is also no evidence 
that AERPs in the LA and distal coronary sinus are 
comparable.
Whether electrical remodeling results in regional 
differences in AERP remains unclear. In goats, 
4  weeks of atrial pacing (BCL, 150  ms) shortened 
AERPs, but it did not result in enhancement of re-
gional AERP differences that were already present 
during sinus rhythm.36
In 29 patients with a history of PAF, AERP at the 
pulmonary veins (PVs) was shorter than both the LA 
and the RA (PV, 174±62  ms; LA, 254±30  ms; RA, 
221±29  ms; P=0.0001).41 In a similar patient popu-
lation, AERP was shorter at the distal PV than the 
PV-LA junction (PAF, N=48; AERP, 177±43 ms versus 
222±30  ms, respectively; P<0.0001).42 Unfortunately, 
spatial distribution of AERP between PV and LA has 
so far not been described in nonremodeled atria, so 
whether electrical remodeling affected regional differ-
ences in AERP is unknown.
IMPACT OF AF ON REFRACTORINESS
In Table 2, clinical studies reporting on AERP meas-
ured in patients with different subtypes of AF and 
control patients are summarized.21,23,25,43-48 In general, 
patients with a history of AF have shorter AERPs than 
patients without AF.21,23,25,30,47–49 In patients with PAF, 
at a BCL of 600  ms, AERP varied between 193±23 
and 310±51 ms. This variation may be, as discussed 
above, attributable to many variables affecting AERP 
measurements, but it may also reflect heterogeneity in 
the AF substrates.
Interestingly, several investigators have reported 
shorter AERP in patients with PAF compared with 
patients with peAF,10 which is in contrast with the 
assumption that persistence of AF progressively 
shortens refractoriness. A possible explanation for 
this observation may be the increased prevalence of 
LA dilatation in patients with peAF, which prolongs 
AERP.27,30,47,49
In absence of atrial dilatation, AERP is shorter in 
patients with peAF than in patients with PAF.47 When 
AERPs were longer in patients with peAF, this could 
be explained by atrial dilatation. Although tachycardia 
initially causes upscaling of K+ ion channel expres-
sion and shortening of repolarization, atrial dilatation 
leads to permanent reduction in both Ca2+ and K+ 
channel expression, resulting in prolonged AERP.4,50,51 
Therefore, because of extensive electrical or structural 
remodelling in peAF, “normalisation” of AERP occurred 
and diminished differences between patients with PAF 
and patients with peAF.10,30,49
FAILURE OF RATE ADAPTATION
Rate adaptation is a dynamic process reflected by 
rate adaptation curves, demonstrating the AERPs at 
different BCLs. Persistent shortening of AERP despite 
cycle length prolongation is referred to as failure of rate 
adaptation and causes attenuation of the rate adapta-
tion curve. This phenomenon has been described in 
isolated human atrial cells of dilated RA appendages,52 
RA canine cells after fast rate activation,4,53 and several 
clinical studies.23,54–56
In a detailed protocol, steepness of rate adapta-
tion curves derived from the LA and RA appendage 
(BCL range, 250–600  ms) were compared between 
anesthetized patients with peAF (N=13), PAF (N=16), 
and no history of AF (N=13) before coronary artery by-
pass surgery.23 The slope of the rate adaptation curve 
was less steep in patients with peAF compared with 
patients with PAF and controls (peAF, 87±57; PAF, 
109±38; no AF, 138±33; P<0.05). This reduction in rate 
adaptation capacity correlated with a progressive de-
crease in protein expression of L-type Ca2+ channel, 
Kv4.3, Kv1.5, hERG, minK, and Kir3.1 in both LA and 
RA appendages. These results indicate that decreas-
ing steepness of the curve may relate to progressive 
ion channel dysfunction and thus to progression of the 
AF substrate.
Likewise, APD restitution, illustrated by fitted curves 
of APD90 plotted against preceding diastolic intervals, 
was less steep in 13 patients with peAF than in 27 pa-
tients with PAF in the LA and PV area.19 Patients in 
the PAF group showed a maximum APD restitution 
slope of 1.5±0.4, whereas in peAF group steepness 
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1.3±0.4 in patients with PAF and 1.5±0.3 in patients with 
peAF (P=NS). In contrast, Kim et al10 also measured 
APD90 using a monophasic action potential catheter 
at 6 locations in the RA and compared APD restitu-
tion between patients with peAF, patients with PAF, 
and patients without AF. The mean slope was steeper 
Table 2. Summary of AERP Comparisons Between Different AF Subtypes
Year of 
Publication,  















HRA, CS … 238±23 215±1*




HRA, CS 600 231±36 193±2*
500 231±32 190±2*
400 234±34 178±4*
1998, Pandozi44 14 peAF Decremental, 2-ms 
steps











RAA 600 265 210*
MLRA 600 228 215
RAA 400 270 200*
MLRA 400 218 216




RA 600 247±25 224±13
RA 400 233±25 215±1*
2001, Brundel23 13 controls, 13 
PAF, 16 peAF
… RAA, LAA 600 291±53 222±1* 208±3*
500 277±42 224±2* 207±2*
400 252±34 216±2* 203±2*
300 224±16 202±20* 189±24*
250 184±5 185±19 172±17




RAA 500 215±29 208±2*




HRA 500 233±29 231±27
LRA 500 229±31 228±27
PCS 500 251±3† 236±3†
DCS 500 258±4† 237±3†
Mean of all 
locations
500 243±27† 233±2†





Left PV 600 257±62
Right PV 600 265±62
Mean of all 
locations
600 283±30
AERP indicates atrial effective refractory period; BCL, basic drive cycle length; DCS, distal coronary sinus; HRA, high right atrium; LA, left atrium; LRA, low 
right atrium; MLRA, midlateral right atrial wall; PAF, paroxysmal atrial fibrillation; PCS, proximal coronary sinus; peAF, persistent atrial fibrillation; PV, pulmonary 
vein; RA, right atrium; and RAS, right atrial septum.
*Significantly different from controls.
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in patients with PAF (1.1±0.4) and peAF (1.4±0.3) than 
in control patients (0.5±0.3, P<0.01), but mutual differ-
ences between AF subtypes were not significant.
The explanation for the contradicting results is un-
known. However, there were differences in measuring 
sites, pacing protocols (eg, extrastimuli or dynamic 
steady-state pacing10), and analysis methodologies, 
each of which affect APD and APD restitution slope 
steepness. In addition, in both rate adaptation curves 
and APD restitution curves, a plateau phase was 
reached. Therefore, the range of BCLs or diastolic in-
tervals along which mean curve steepness is calcu-
lated may determine mean adaptation slope as well.
However, in all of the above-mentioned studies, it 
was not reported whether AF was induced or pres-
ent before surgery. This may be of importance, as 
failure of rate adaptation restores after restoration of 
sinus rhythm. Yu et al55 compared 19 patients with 
peAF (>6 months) to 20 age-matched controls with-
out a history of AF or atrial flutter. In the peAF group, 
rate adaptation curves constructed from AERPs at 
the RA appendage and distal coronary sinus 30 min-
utes after cardioversion were less steep (RA: slope, 
0.049±0.024 versus 0.074±0.016; distal coronary 
sinus: slope, 0.098±0.042 versus 0.162±0.040, re-
spectively; both P<0.01). After 4 days of sinus rhythm, 
however, rate-adaptation curves no longer differed 
from the curves obtained from the control group 
(0.066±0.101 versus 0.162±0.040; P>0.05), indicat-
ing that tachycardia-induced impairment of rate ad-
aptation can be transient in nature. Additional studies 
are necessary to establish whether the slope of rate 
adaptation can be used to distinguish between dif-
ferent AF subtypes, taking into account duration of 
sinus rhythm and AF episodes.
INTERREGIONAL VERSUS 
INTRAREGIONAL DISPERSION OF 
REFRACTORINESS
Heterogeneous manifestation of electrical remod-
eling throughout the atria causes increased disper-
sion of refractoriness, which is generally accepted as 
one of the key players in AF onset and maintenance. 
As a consequence, for example, unidirectional con-
duction block of short-coupled ectopic beats caused 
by localized areas of prolonged refractoriness may 
initiate reentry.
There are generally 2 ways to measure “disper-
sion of refractoriness.” In many studies, dispersion of 
AERP is defined as the maximum difference in AERP 
between varying atrial regions—in other words, inter-
regional differences. For the sake of clarity, studies in 
which dispersion is defined as the difference between 
minimum and maximum AERPs from varying regions 
are referred to as studying interregional dispersion. 
When mapping data with a high spatial resolution (in-
cluding multiple AERPs per anatomic region) is used 
and intraregional differences are defined by a mathe-
matical measure of variation, this will be referred to as 
intraregional dispersion.
INTERREGIONAL DISPERSION 
RELATED TO AF SUBTYPES
Several studies have compared interregional disper-
sion of AERP between patients with and without AF. 
In each of these studies, a different set of recording 
sites was used, composed of only RA or both RA and 
LA recording sites, hampering comparison of study 
outcomes.
Interregional AERP dispersion between the high, 
mid, and lower RA wall was increased in 23 patients 
with PAF compared with 20 patients without AF 
(45±28 versus 34±13; P<0.05).57 However, increased 
interregional AERP dispersion between the RA ap-
pendage and mid RA was demonstrated in 8 patients 
without AF compared with 13 patients with peAF (dis-
persion, 54 ms versus 18 ms, respectively; P<0.01).58 
There were also no differences in interregional AERP 
dispersion when 6 measuring sites throughout the 
RA were compared between patients with peAF 
(N=18), PAF (N=14), and no history of AF (N=9). The 
average amounts of interregional dispersion in AERP 
were 32.4±30.3 ms (peAF), 41.7±27.4 ms (PAF), and 
32.7±19.2  ms (no AF), respectively (P values not 
provided).10
Likewise, when 3 RA and LA sites were combined, 
there was no difference in interregional dispersion be-
tween patients with peAF (N=11), PAF (N=8), and no 
history of AF (N=10).30 Other studies demonstrated in a 
similar patient population that interregional dispersion 
of AERP was increased in patients with AF compared 
with patients without AF (peAF, N=18; PAF, N=22; no 
AF, N=19, corresponding to dispersions of 44.0±18.5, 
49.3±29.9 and 23.5±14.1  ms, respectively; ANOVA, 
P<0.01).49
In a larger cohort of patients with AF (PAF, N=343; 
peAF, N=140), interregional dispersion in AERP be-
tween 4 LA and RA sites was 56.3±34.8 ms in PAF 
versus 44.6±25.0 in peAF (P<0.001).47 Patients were 
excluded when AERP could not be determined be-
cause of AF induction. These excluded patients may 
be especially interesting as the arrhythmogenic sub-
strate may be more pronounced, but it was not re-
ported whether they were included in the peAF or PAF 
group.
In conclusion, evidence is conflicting with respect 
to interregional dispersion in AERP. Although interre-
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compared with patients without a history of AF, there is no 
evidence that interregional AERP dispersion is enhanced 
in patients with peAF compared with patients with PAF.
AERP in peAF was less dispersed than in patients 
with PAF and even than in patients without AF.10,43,47 This 
observation is not in line with the assumption that in-
creased dispersion of AERP is associated with a more 
elaborate arrhythmogenic substrate in patients with 
peAF. It is unclear why reduced interregional dispersion 
was found in these patients with more progressive stages 
of remodeling. General shortening of the AERP may re-
duce regional differences. This was previously reported 
by Wijffels et al7 who used an epicardial array containing 
6 electrodes (interelectrode distance, 6–10 mm) to de-
termine interregional dispersion of AERP between the 
RA appendage and LA appendage in 5 goats before AF 
induction, 24 and 48 hours after induction of sustained 
AF. Regional differences in AERP were 14, 22, 20, and 
16 ms at BCLs of 400, 300, 250, and 200 ms, respec-
tively, compared with 8, 8, 6, and 8 ms after 48 hours of 
AF (P value not provided). Although they described AF 
up to only 48 hours after induction, the same principle 
may apply to a general shortening of AERP in patients 
with peAF compared with patients with PAF.
Whether differences in interregional dispersion 
were mainly caused by shorter minimum or longer 
maximum AERPs was not reported in any of the clin-
ical studies reporting on interregional dispersion of 
AERP. Also, as dispersion in refractoriness is already 
demonstrated in closely adjacent RA sites,10 the rel-
evance of randomly chosen, widely spaced atrial 
sites for the assessment of interregional dispersion 
is questionable. Increased spatial density of AERP 
measurements leading to a more detailed assess-
ment of AERP distribution throughout the atria (in-
traregional dispersion) may be required to elucidate 
these remaining questions.
INTRAREGIONAL DISPERSION 
RELATED TO AF SUBTYPES
Pacing in ex vivo rabbit atrial myocardium revealed that a 
minimum difference of 11 to 16 ms in AERP between ad-
jacent electrodes (interelectrode distance unknown) was 
associated with local conduction block during prema-
ture extrastimuli.59 Dispersion of refractoriness will thus 
lead to a frequency-dependent, scattered, and variable 
pattern of lines of conduction block, creating a substrate 
for the onset and maintenance of reentry circuits.
The relation between activation rate and dispersion 
in AERPs was first demonstrated in an experimental 
canine model by Fareh et al.29 Dispersion of refrac-
toriness was defined as the coefficient of variation of 
AERPs (standard deviation/mean AERP) at 73 sites on 
the epicardium (interelectrode distance not provided). 
The coefficient increased from 13.5% to 21.7% (P value 
not provided) during 24  hours of fixed-rate pacing 
(BCL, 150 ms) and was associated with increased sus-
ceptibility to AF induction (r=0.81; P<0.001). In addition, 
Li et al58 discovered a 3-fold increase in intraregional 
dispersion of refractoriness in patients with PAF (N=21) 
compared with patients with acutely induced AF (N=12), 
defining dispersion as variance (squared SD) among 
the fifth percentile AF cycle length of 5 to 16 sites in RA 
and LA (AERP variance, 717±469 ms; acutely induced 
AF, 299±123 ms, respectively; P<0.05). The observed 
differences could mainly be attributed to shorter fifth 
percentile in the PAF group.
These studies support the hypothesis that in-
creased intraregional dispersion of refractoriness 
causes increased susceptibility to AF. Unfortunately, 
no other studies have yet reported on the dispersion 
of refractoriness in patients with peAF. Whether intra-
regional dispersion is best represented by these meth-
odologies and whether they can be used to distinguish 
between different degrees of the arrhythmogenic sub-
strate is yet to be discovered.
PREDICTION OF AF ONSET
In 734 patients with atrioventricular nodal reentrant 
tachycardia or a concealed bypass tract (N=1308; 
age, 44±16  years), spontaneous onset of AF within 
12 years was enhanced if AERP at the high RA was 
>280 ms (BCL, 600 ms in 93%; hazard ratio adjusted 
for age, 2.08; P  =0.041).28 This seems to contrast 
with the association between short AERPs and AF. 
However, patients with AERP ≥280 ms (n=34; 10.3%) 
also had larger LA size (41±6 mm versus 36±6 mm; 
P<0.001), which, as previously discussed, prolongs 
AERP. When an AERP of 280 ms is compared with 
AERPs measured in nonremodeled RA of nonanes-
thetized patients (Table 1), 280 ms indeed seem dis-
proportionally long.
Interregional dispersion in AERP of >76 ms between 
high RA, low RA, and distal and proximal coronary sinus 
was related to AF onset within 24  months after abla-
tion of an atrioventricular bypass or slow atrioventricu-
lar node pathway in 845 patients (area under the curve, 
0.896; 95% CI, 0.833–0.959; P<0.05).60 Sensitivity and 
specificity were not provided, nor was the stimulation 
protocol. Although prior atrial tachycardia was an exclu-
sion criterion, the authors mention AF recurrence rather 
than onset, suggesting that AF had occurred before.
PREDICTION OF SUSCEPTIBILITY TO 
AF INDUCTION
AERP has also been used to predict susceptibil-
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demonstrated that enhanced susceptibility to AF 
induction was associated with shorter AERPs. In 
both isolated and in vivo canine atria, shortening of 
AERP was associated with increased inducibility of 
sustained AF.61,62 Pharmacologically induced AERP 
shortening increased susceptibility to AF induction 
in dogs,63 whereas AERP prolongation reduced AF 
inducibility in swine.64
In clinical studies, there was no relation between 
AERP and AF inducibility in patients with or without 
structural heart disease and with supraventricular 
tachycardia, when defining successful induction as 
AF lasting either >10 seconds (N=50)65 or >5 minutes 
(N=44).66,67 A possible explanation for the disparate 
outcomes is that AERP by itself does not reflect the ar-
rhythmogenic substrate. In a canine model, increased 
intraregional dispersion of AERP, defined as covari-
ance among 96 epicardial sites, was an independent 
risk factor for AF induction (stepwise multilinear re-
gression; P<0.0001), whereas ERP alone was not.29
Interregional dispersion was related to successful 
AF induction both in experimental and clinical stud-
ies but could not be used to identify patients at risk of 
AF persistence.62,67 In a canine model (anesthesized, 
hypothermic, vagal stimulation), interregional disper-
sion between the sinus node area, the low posterior 
RA, and the distal coronary sinus was increased in 
dogs susceptible to AF induction (59±24  ms versus 
29±18 ms; P<0.001).62 Similarly, in patients with a his-
tory of PAF, interregional dispersion between the high 
RA, low RA, interatrial septum, and proximal and distal 
coronary sinus was larger in the AF inducible group 
(N=22; 105±78  ms) than in the noninducibility group 
(N=11; 49±20 ms; P<0.05).68 In a follow-up study, how-
ever, interregional dispersion did not differ between pa-
tients in whom induced AF terminated spontaneously 
or persisted.67
The occurrence of APD alternans may also pre-
dict susceptibility to AF induction. In a small study 
of 12 patients with peAF, 13 patients with PAF, and 8 
patients without a history of AF, APD alternans pre-
ceded all successful AF inductions.11 In cases where 
APD alternans had disappeared because of loss 
of capture, AF was noninducible. In addition, in 19 
patients without structural heart disease, especially 
discordant APD alternans was related to AF induc-
ibility.69 Discordant alternans was evoked in 13 of 19 
(46%) patients and followed by AF initiation in 8 of 
them (P=0.012).
It is unclear, however, whether susceptibility to AF 
induction relates to AF onset or recurrence in real life. 
Moreover, induction protocols vary considerably, jeop-
ardizing validity and reproducibility of study results, as 
susceptibility to AF induction is strongly dependent on, 
for example, the number of induction attempts and 
stimulus strengths.66
PREDICTION OF EARLY 
POSTOPERATIVE AF
In 56 patients admitted for coronary artery bypass 
grafting (AF, N=18; no AF, N=38), interregional disper-
sion of refractoriness (high RA, posterolateral RA, dis-
tal coronary sinus) was an independent predictor of 
postoperative AF incidence (odds ratio, 1.29; 95% CI, 
1.12–1.47; P<0.001).70 It was not reported which patient 
group showed more interregional dispersion.
PREDICTION OF SUCCESSFUL 
ABLATIVE THERAPY
In 67 patients with both an accessory pathway and 
AF, the relation between interregional dispersion 
and recurrence rate was used to predict which pa-
tients benefit from PV isolation (PVI) concomitant 
to ablation of the accessory pathway. Concomitant 
PVI was performed in 29 patients. Interregional 
dispersion of >75 ms was related to AF recurrence 
within 36 months (sensitivity, 70%; specificity, 92%; 
P=0.003). If dispersion was >75  ms (PVI, N=9; no 
PVI, N=11), concomitant PVI resulted in lower recur-
rence rates (2 [18.2%]) than pathway ablation alone 
(7 [77.8%]; P=0.012). When dispersion was <75 ms, 
no difference in recurrence rates was established be-
tween the PVI (N=18) and non-PVI groups (N=25).71 
The way in which patients were assigned to the PVI 
or non-PVI group is not described; however, interre-
gional dispersion was similar in both groups. These 
results suggest that regional differences in refractori-
ness may aid in selecting patients who will benefit 
most from additional PVI ablation therapy, but addi-
tional research will have to be performed to confirm 
and solidify these outcomes.
CURRENT APPLICABILITY 
OF REFRACTORINESS AS AN 
ELECTRICAL BIOMARKER
AF-induced electrical remodeling is related to AERP 
shortening, dispersion of refractoriness, and attenu-
ated slopes of AERP–rate adaptation curves. However, 
none of the reviewed parameters seem to have a 
strict linear relation with the arrhythmogenic substrate 
underlying AF. Although differences in refractoriness 
have been demonstrated between patients with dif-
ferent AF subtypes, considerable overlap in AERPs 
is observed. Construction of, for instance, receiver 
operating characteristic curves to further examine the 
predictive value of AF may be useful.
In many studies, environmental factors influencing 
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factors may include the pacing protocol (measuring site, 
stimulus strength, BCL), data processing (eg, choosing 
the appropriate blanking period for determination of 
local activation time), atrial dilatation, stimulation of the 
autonomous nervous system, cardio-active medica-
tion (usage of antiarrhythmic medication, anesthetics), 
and phases of electrical (reverse) remodeling (such as 
time since AF onset/induction, time since conversion 
to sinus rhythm). Therefore, standardized pacing proto-
cols and elaborate documentation are required to ac-
curately measure AERP and compare study outcomes.
There are several hurdles to overcome in order to 
establish whether AERP is a suitable biomarker for 
staging of AF. For example, as there are most likely 
both interregional and intraregional differences in 
AERPs, a detailed map of refractoriness is essential 
to gain insight into dispersion in refractoriness in both 
nonremodeled and remodeled atria.
Determination of AERP during AF, however, as is 
required for patients in whom cardioversion cannot 
be accomplished, may be even more problematic. As 
discussed above, the reliability of the minimum or 5th 
percentile of the AF cycle length histogram as a re-
flection of AERP is questionable. In addition, the AERP 
changes from beat to beat because of variability in pre-
ceding fibrillation intervals.
Another patient group in whom AERP may not have 
been determined accurately so far includes patients 
who are susceptible to AF induction. They are often 
excluded from analysis when no AERP can be deter-
mined because of repetitive AF induction. This could 
have resulted in distortion of study results, as refrac-
toriness especially in these patients may be altered. 
Using incremental instead of decremental extrastimuli 
protocols may reduce this problem, as there will be no 
need for repetitive electrical cardioversion and restart-
ing of the pacing sequence.
At present, interregional dispersion has been stud-
ied more frequently than intraregional dispersion of 
AERP, which does not seem to reflect the arrhythmo-
genic substrate adequately and is therefore unsuitable 
as a biomarker. Research into the prognostic value of 
AERP-derived parameters is limited and needs further 
investigation.
In the future, pairing refractoriness with addi-
tional electrical biomarkers may be considered as 
well, as AERP is not the only factor that influences 
susceptibility to AF. Whereas electrical remodeling 
appears to play a key role in the initiation of AF, addi-
tional structural remodeling has proven to be crucial 
for persistence of the tachyarrhythmia. Progressive 
wavelength shortening was demonstrated in a canine 
model after rapid pacing (BCL, 150 ms)24 and in goats 
with artificially sustained AF,7 increasing susceptibility 
to AF induction and enhancing spatiotemporal disor-
ganization of waves in persistent AF. This occurred a 
considerable period after AERP had reached a new 
steady state, increasing stability of AF. This indicated 
that electrical remodeling alone may not cover the full 
extent of the arrhythmogenic substrate.
AF persistence may depend on the combination of 
electrical (AERP shortening) and structural remodeling 
(such as reduced conduction velocity attributable to, 
eg, fibrosis or nonuniform anisotropy) rather than AERP 
alone.72 Therefore, other dynamic electrical character-
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